Cargando…

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations

SIMPLE SUMMARY: High-grade serous ovarian cancer (HGSOC) is the most frequent and lethal form of ovarian cancer and is associated with homologous recombination deficiency (HRD) in 50% of cases. This specific alteration is associated with sensitivity to PARP inhibitors (PARPis). Despite vast prognost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quesada, Stanislas, Fabbro, Michel, Solassol, Jérôme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909526/ https://www.ncbi.nlm.nih.gov/pubmed/35267439 http://dx.doi.org/10.3390/cancers14051132

Ejemplares similares

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
por: Quesada, Stanislas, et al.
Publicado: (2022)

Homologous Recombination Deficiency: Concepts, Definitions, and Assays
por: Stewart, Mark D, et al.
Publicado: (2022)

Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
por: Chiang, Ying-Cheng, et al.
Publicado: (2021)

Tumor homologous recombination deficiency assays: another step closer to clinical application?
por: Stecklein, Shane R, et al.
Publicado: (2014)

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
por: da Cunha Colombo Bonadio, Renata Rodrigues, et al.
Publicado: (2018)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020)

The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
por: van Wijk, Lise M., et al.
Publicado: (2020)

Homologous Recombination Deficiencies and Hereditary Tumors
por: Yamamoto, Hideki, et al.
Publicado: (2021)

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
por: Watkins, Johnathan A, et al.
Publicado: (2014)

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
por: Takaya, Hisamitsu, et al.
Publicado: (2020)

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches
por: Mangogna, Alessandro, et al.
Publicado: (2023)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
por: Patel, Jai N., et al.
Publicado: (2018)

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature
por: Frey, Melissa K., et al.
Publicado: (2017)

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma
por: Shi, Zhiwen, et al.
Publicado: (2021)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

Pan-cancer landscape of homologous recombination deficiency
por: Nguyen, Luan, et al.
Publicado: (2020)

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
por: Wattenberg, Max M., et al.
Publicado: (2021)

Targeting homologous recombination deficiency in uterine leiomyosarcoma
por: Dall, Genevieve, et al.
Publicado: (2023)

Leveraging homologous recombination repair deficiency in sarcoma
por: Slade, Dea, et al.
Publicado: (2023)

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
por: Akinjiyan, Favour A., et al.
Publicado: (2023)

Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma
por: Liu, Hangqi, et al.
Publicado: (2022)

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
por: How, Jeffrey A., et al.
Publicado: (2021)

Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination
por: Setton, Jeremy, et al.
Publicado: (2021)

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
por: Ngoi, N.Y.L., et al.
Publicado: (2021)

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer
por: Wen, Hao, et al.
Publicado: (2022)

Homologous recombination proficiency in ovarian and breast cancer patients
por: Creeden, Justin Fortune, et al.
Publicado: (2021)

Echocardiography in Pulmonary Arterial Hypertension: Comprehensive Evaluation and Technical Considerations
por: Topyła-Putowska, Weronika, et al.
Publicado: (2021)

Surgical approach to giant ovarian masses in adolescents: technical considerations
por: Persano, Giorgio, et al.
Publicado: (2018)

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking
por: Tsantikidi, Aikaterini, et al.
Publicado: (2023)

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests
por: Meijer, Titia G., et al.
Publicado: (2022)

Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions
por: Zhang, Meng, et al.
Publicado: (2021)

Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery
por: Yi, Huan, et al.
Publicado: (2022)

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
por: Xie, Tao, et al.
Publicado: (2022)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
por: Pikkusaari, Sanna, et al.
Publicado: (2023)

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer
por: Romeo, Margarita, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6e531ukoftcm2uvj989pjv3ald